Benidipine

ID: ALA2218858

Chembl Id: CHEMBL2218858

PubChem CID: 60065

Max Phase: Preclinical

Molecular Formula: C28H31N3O6

Molecular Weight: 505.57

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@@H]2CCCN(Cc3ccccc3)C2)C1c1cccc([N+](=O)[O-])c1

Standard InChI:  InChI=1S/C28H31N3O6/c1-18-24(27(32)36-3)26(21-11-7-12-22(15-21)31(34)35)25(19(2)29-18)28(33)37-23-13-8-14-30(17-23)16-20-9-5-4-6-10-20/h4-7,9-12,15,23,26,29H,8,13-14,16-17H2,1-3H3/t23-,26?/m1/s1

Standard InChI Key:  QZVNQOLPLYWLHQ-GEPVFLLWSA-N

Alternative Forms

1. Parent:

   

   ALA2218858

   BENIDIPINE

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 505.57

Molecular Weight (Monoisotopic): 505.2213

AlogP: 4.21

#Rotatable Bonds: 7

Polar Surface Area: 111.01

Molecular Species: NEUTRAL

HBA: 8

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 9

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 8.09

CX LogP: 4.02

CX LogD: 3.26

Aromatic Rings: 2

Heavy Atoms: 37

QED Weighted: 0.34

Np Likeness Score: -0.95

References

1. Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K..  (2002)  Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression.,  16  (1): [PMID:12128170] [10.1016/s0928-0987(02)00082-9]

2. Katoh M, Nakajima M, Yamazaki H, Yokoi T..  (2000)  Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4.,  17  (1): [PMID:11145223] [10.1023/a:1007568811691]

3. Bellera CL, Balcazar DE, Vanrell MC, Casassa AF, Palestro PH, Gavernet L, Labriola CA, Gálvez J, Bruno-Blanch LE, Romano PS, Carrillo C, Talevi A..  (2015)  Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.,  93  [PMID:25707014] [10.1016/j.ejmech.2015.01.065]

4. Wiśniowska B, Mendyk A, Fijorek K, Glinka A, Polak S..  (2012)  Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.,  32  [PMID:22761000] [10.1002/jat.2784]

5. Sutherland JJ, Yonchev D, Fekete A, Urban L..  (2023)  A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.,  14  (1): [PMID:37468498] [10.1038/s41467-023-40064-9]

Source

Source(2):

• Scientific Literature
• TP-search Transporter Database